Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2-Reference-Cited by-同舟云学术

Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2

Published:2007-10-30 Issue:2 Volume:25 Page:182-186
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Rubenstein Marvin,Tsui Paulus,Guinan Patrick

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-007-9018-y.pdf

Reference17 articles.

1. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Meth Find Clin Pharmacol 1998;20:825–31.

2. Rubenstein M, Guinan P. A review of various antisense oligonucleotide therapeutic approaches for prostate cancer. Prostate J 2000;2:179–88.

3. Rubenstein M, Glick R, Lichtor T, Mirochnik Y, Chou P, Guinan P. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor. Med Oncol 2001;18:121–30.

4. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Med Oncol 2007;24:189–96.

5. Rubenstein M, Tsui P, Guinan P. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors (in press; Med Oncol 2007;24).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In LNCaP Cells Inhibition of BCL-2 by Antisense Oligonucleonucleotides Results in Compensatory Changes in Apoptosis;Scientific Journal of Genetics and Gene Therapy;2014-03-27

2. c-Src Antisense Complexed with PAMAM Denderimes Decreases of c-Src Expression and EGFR-Dependent Downstream Genes in the Human HT-29 Colon Cancer Cell Line;Asian Pacific Journal of Cancer Prevention;2012-05-30

3. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR;Medical Oncology;2011-05-15

4. Bax expression remains unchanged following antisense treatment directed against BCL-2;Medical Oncology;2010-04-27

5. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR;Medical Oncology;2009-11-24